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Abstract
Methionine-1 (M1)-linked polyubiquitin chains conjugated by the linear ubiquitin chain assembly complex (LUBAC)
control NF-κB activation, immune homoeostasis, and prevents tumour necrosis factor (TNF)-induced cell death. The
deubiquitinase OTULIN negatively regulates M1-linked polyubiquitin signalling by removing the chains conjugated by
LUBAC, and OTULIN deficiency causes OTULIN-related autoinflammatory syndrome (ORAS) in humans. However, the
cellular pathways and physiological functions controlled by OTULIN remain poorly understood. Here, we show that
OTULIN prevents development of liver disease in mice and humans. In an ORAS patient, OTULIN deficiency caused
spontaneous and progressive steatotic liver disease at 10–13 months of age. Similarly, liver-specific deletion of OTULIN in
mice leads to neonatally onset steatosis and hepatitis, akin to the ORAS patient. OTULIN deficiency triggers metabolic
alterations, apoptosis, and inflammation in the liver. In mice, steatosis progresses to steatohepatitis, fibrosis and pre-
malignant tumour formation by 8 weeks of age, and by the age of 7–12 months the phenotype has advanced to malignant
hepatocellular carcinoma. Surprisingly, the pathology in OTULIN-deficient livers is independent of TNFR1 signalling.
Instead, we find that steatohepatitis in OTULIN-deficient livers is associated with aberrant mTOR activation, and inhibition
of mTOR by rapamycin administration significantly reduces the liver pathology. Collectively, our results reveal that
OTULIN is critical for maintaining liver homoeostasis and suggest that M1-linked polyubiquitin chains may play a role in
regulation of mTOR signalling and metabolism in the liver.
Introduction
Liver cancer is second most frequent cause of cancer-related
deaths worldwide [1]. Nearly all cases of hepatocellular car-
cinoma (HCC), the most common form of liver cancer, are
caused by either chronic liver inflammation (hepatitis) and/or
metabolic alterations, which mechanistically are linked to
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hepatocyte cell death, compensatory regeneration, and
excessive mammalian target of rapamycin (mTOR) activation
[1–3]. Chronic inflammation and sustained compensatory
proliferation induced by hepatocyte damage is pro-
tumourigenic and leads to accumulation of mutations and
epigenetic changes over time [4, 5]. Pro-inflammatory med-
iators in the microenvironment support the continuous pro-
liferation and expansion of pre-neoplastic cells, eventually
leading to hepatocyte transformation and cancer [6]. Under-
standing the cellular processes that contribute to the patho-
genesis of chronic liver disease resulting in HCC is therefore
important to identify new and better therapeutic strategies.
Multiple regulatory mechanisms in inflammation rely on
signalling via non-degradative protein ubiquitination [7].
Methionine-1 (M1)-linked ubiquitin (Ub) chains (hereafter
referred to as M1-polyUb) are conjugated by the linear Ub
chain assembly complex (LUBAC), consisting of the cata-
lytic subunit HOIP and the co-activators HOIL-1 and
SHARPIN [8]. M1-polyUb regulates pro-inflammatory
nuclear factor-κB (NF-κB) signalling, gene activation, and
cell death in response to engagement of tumour necrosis
factor (TNF) receptor 1 (TNFR1) and a range of other
immune receptors [8, 9]. LUBAC is recruited to the TNFR1
receptor signalling complex where it conjugates M1-polyUb
to activate IκB kinase (IKK) and NF-κB [8, 10]. However,
without LUBAC and M1-polyUb, TNFR1 signalling is
shifted from pro-inflammatory gene activation towards
induction of cell death [10, 11], which can occur via
caspase-dependent apoptosis or caspase-independent
necroptosis [12–17]. Dysregulated TNFR1 and NF-κB
signalling have been implicated in the pathogenesis of
hepatitis and HCC [2, 18], and several studies have linked
regulators of M1-polyUb signalling, including NF-κB
essential modulator (NEMO) and HOIP, to the develop-
ment of liver disease and cancer [19–21].
Ub signalling is antagonised by deubiquitinases
(DUBs), which cleave the polyUb signal from substrates to
terminate signalling [22]. OTU DUB with linear linkage
specificity (OTULIN) and CYLD are the two main DUBs
that regulate M1-polyUb signalling [23, 24]. OTULIN
exclusively cleaves M1 linkages [25, 26], whereas CYLD
cleaves both M1 and K63 linkages [27]. OTULIN binds
directly to the LUBAC subunit HOIP [28–30] and reg-
ulates LUBAC signalling, autoubiquitination, and stability
[25, 31–35]. In humans, homozygous mutations in OTU-
LIN cause OTULIN-related autoinflammatory syndrome
(ORAS) (also known as otulipenia or autoinflammation,
panniculitis, and dermatosis syndrome; OMIM #617099),
a life-threatening autoinflammatory disease characterised
by fevers, panniculitis, diarrhoea, and arthritis
[31, 32, 36, 37]. The primary driver of inflammation in
OTULIN-deficient humans and mice is TNF signalling
[31, 36], which in myeloid cells leads to LUBAC hyper-
signalling and NF-κB activation [31, 32]. In other cell
types, e.g. fibroblasts, OTULIN loss leads to LUBAC
degradation and TNF-induced cell death [32, 33]. CYLD
acts as a tumour suppressor and is mutated in a range of
human cancers [38]. However, it remains unknown if
OTULIN deficiency also promotes development of cancer
or other pathologies.
In this study, we identify OTULIN as critical for pre-
venting liver disease in mice and humans. We demonstrate
that OTULIN deficiency causes steatohepatitis, fibrosis, and
HCC in mice. Surprisingly, the liver pathology is inde-
pendent of TNFR1 signalling, but partially dependent on
mTOR activity. Consistently, treatment with the mTOR




The Otulindel/flox and Otulin-Rosa26-Cre-ERT2 mice, and
the generation of bone marrow chimeras were described
previously [31]. For chimeras, sex-matched 4–5-month-
old Rosa26-Cre-ERT2-Otulin+/flox (ControlChim) or -Otu-
lindel/flox (Otulin-KOChim) mice were used as recipients.
After reconstitution, three doses of tamoxifen (Sigma, St.
Louis, MO; 1 mg in sunflower oil with 10% ethanol per
dose) were given i.p. to induce OTULIN deletion [31].
OtulinΔhep mice with deletion of OTULIN in hepatocytes
were generated by breeding Otulindel/flox mice with mice
expressing Cre from a serum albumin promoter (Alb-Cre)
[39]. Experimental OtulinΔhep mice were either Otulinflox/
flox; Alb-CreTg+ or Otulindel/flox; Alb-CreTg+. Control mice
were Otulin+/flox; Alb-CreTg+ or occasionally wild type
C57BL/6. Mice were matched for age and sex whenever
possible. No method of randomisation was applied. All
mice were housed under specific pathogen-free condi-
tions. Tnfr1−/− mice [40] and the Alb-Cre mice were
obtained from The Jackson Laboratory, Bar Harbor, ME.
All experiments were conducted with the approval of the
United Kingdom Home Office and the MRC Centre
Ethical Review Committee.
Human subjects
ORAS Patient IV:3 [31] was evaluated at Birmingham
Children’s Hospital, UK. Written informed consent was
obtained from the patient and family members. The study
was approved by the South Birmingham Research Ethics
Committee and performed in accordance with the 1964
Declaration of Helsinki. For further details on patient I:V3,
see Damgaard et al. [31].
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Rapamycin treatment of OtulinΔhep mice
OtulinΔhep and control mice were bred by timed matings.
Dams pregnant with pups to be allocated to rapamycin-treated
groups received one i.p. injection of rapamycin (1mg/kg) at
E17.5. After birth, pups were allocated to experimental
groups based on their genotype and fostered onto pseudo-
pregnant CD-1 mothers. At postnatal day 3 (P3), lactating
CD-1 foster mothers received one dose of rapamycin
(1 mg/kg) or vehicle s.c. From P8, pups were injected i.p.
with rapamycin or vehicle twice weekly until 8 weeks of age.
Mice received increasing doses of rapamycin as follows: P3,
20 μg; P11, 25 μg; P15, 30 μg; P18, 35 μg; P22, 135 μg; P25,
180 μg; P29, 240 μg; P32, 240 μg; P36, 300 μg; P39, 300 μg;
P43, 330 μg; P46, 330 μg; P50, 330 μg; P53 360 μg; P57, 360
μg; equivalent to 1 mg/kg between P8 and P18 and 3mg/kg
from P22 until the end of the experiment. Mice that met a
humane endpoint before the age of 39 days were excluded
from analyses. Rapamycin (LC Laboratories, Woburn, MA)
was dissolved in 70% ethanol at 20mg/mL and diluted to
0.2–0.6 mg/mL in sterile PBS containing 0.5% (v/v) Tween-
80 (VWR, Lutterworth, UK) and 0.5% (v/v) PEG-400
(Hampton Research, Aliso Viejo, CA) before injection.
Blood cell counts
Whole blood from terminal bleeds was collected in EDTA-
containing Blood Collection Tubes (Greiner GmbH,
Kremsmünster, Austria) and analysed on a scil Vet
abcPlus+ haematological analyser (scil Animal Care Com-
pany, Gurnee, IL).
Histology
Mouse tissue samples were fixed in 10% neutral buffered
formalin (Sigma) for 24 h at room temperature. For fresh
frozen sections, samples were embedded in OCT Embedding
Medium (Thermo Scientific, Waltham, MA). Tissues were
sectioned and stained with Haematoxylin and Eosin (H&E),
picro sirius red (PSR), periodic acid–schiff (PAS), and Oil
Red O at AML Laboratories, Inc., Jacksonville, FL, or
Cambridge Stem Cell Institute Histology Core Facility, Uni-
versity of Cambridge, UK. Patient biopsies were processed
and H&E stained at Birmingham Children’s Hospital, UK.
Immunohistochemistry (IHC) and TUNEL assay
All stainings were performed on FFPE sections. For IHC,
antigen retrieval was performed in citric acid buffer, pH 6.0,
for 15 min at 100 °C. Slides were incubated with primary
antibodies (anti-OTULIN, Abcam, or anti-Ki67, Thermo
Scientific; see Table S1) at 4 °C overnight and secondary
biotinylated antibodies for 30 min at room temperature.
Secondary antibodies were labelled using the VECTAS-
TAIN ABC HRP Kit (cat# PK-4001, Vector Laboratories,
Burlingame, CA) and detected using the DAB (3,3′-dia-
minobenzidine) Peroxidase (HRP) Substrate Kit (cat# SK-
4100, Vector Laboratories). TUNEL (terminal deox-
ynucleotidyl transferase dUTP nick end labelling) assays
were performed using the ApopTag Peroxidase In Situ
Apoptosis Detection kit (cat# S7100, Merck Millipore,
Burlington, MA).
Micrographs and image analysis
Micrographs were taken on an Axioplan microscope (Carl
Zeiss) mounted with a Leica DFC310 FX camera using the
Leica LAS software. Contrast, brightness, and colour bal-
ance were adjusted using Adobe Photoshop. Counting of
stained cells, nuclear diameter measurements, and analysis
of fibrotic area were performed in the ImageJ or Fiji soft-
ware. Scale bars represent 200 μm unless otherwise indi-
cated. Image analyses were not blinded.
Serum and plasma analyses
Serum concentrations of mouse alpha-Fetoprotein (AFP)
and mouse insulin were measured using the Mouse AFP
Quantikine ELISA Kit (cat# MAFP00; R&D Systems,
Minneapolis, MN) and Mouse/Rat Insulin Kit (cat#
K152BZC-3; MesoScale Discovery, Rockville, MD),
respectively. Serum levels of mouse albumin, bilirubin,
glucose, triglycerides, cholesterol, alanine aminotransferase
(ALT), and aspartate aminotransferase (AST) were mea-
sured on a Dimension EXL Analyser (Siemens Healthcare,
Erlangen, Germany) using the DF13, DF167, DF30,
DF69A, DF27, DF143, and DF41A cartridges (Siemens
Healthcare), respectively. Patient ALT, γ-glutamyl trans-
peptidase (γGT), and alkaline phosphatase (ALP) levels
were measured in plasma using a Vitros 250 or Vitros 750
analyser (Johnson & Johnson Clinical Diagnostics,
Rochester, NY).
Flow cytometry
Analysis of chimerism in ControlChim and Otulin-KOChim
mice was performed on splenocytes as previously described
[31]. Splenocytes were stained with BrilliantViolet-510-
coupled anti-CD45.1 (BioLegend, San Diego, CA) and
AlexaFluor-700-coupled anti-CD45.2 (eBioscience, San
Diego, CA).
Purification of endogenous polyUb conjugates
GST-tagged TUBE and M1-SUB were purified from
Escherichia coli as previously described [32] and
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endogenous polyUb conjugates were purified from mouse
livers as described previously [32, 34, 35]. Briefly, liver
tissue was lysed on a TissueLyser II (QIAGEN, Hilden,
Germany) in TUBE buffer [32, 34, 35]. GST-tagged
TUBE (50 μg/mL) or M1-SUB (100 μg/mL) was added to
the lysis buffer immediately before lysis and the lysate
incubated with Glutathione Sepharose 4B resin (GE
Healthcare, Chicago, IL) for 16–20 h at 4 °C on rotation.
Bound material was released by mixing the resin with 1×
sample buffer (50 mM Tris pH 6.8, 10% (v/v) glycerol,
100 mM DTT, 2% (w/v) SDS, and 0.01% (w/v)
bromophenol blue).
Immunoblotting
Mouse livers were lysed in RIPA buffer (50 mM Tris pH
7.4, 1% NP-40 (v/v), 0.5% deoxycholate (w/v), 0.1% SDS
(w/v), 150 mM NaCl, 2 mM EDTA, and 5 mM MgCl2)
supplemented with complete protease inhibitor cocktail
(Roche, Basel, Switzerland) and PhosSTOP phosphatase
inhibitor (Roche) on a TissueLyser II (QIAGEN) as pre-
viously described [31]. Samples were resolved on 4–12%
Bis-Tris NuPAGE or Novex WedgeWell 4–20% Tris-
Glycine gels (Life Technologies, Carlsbad, CA) and trans-
ferred to nitrocellulose or PVDF membranes. Membranes
were blocked in 5% (w/v) skimmed milk powder dissolved
in TBS+ 0.1% (v/v) Tween-20 (TBS-T) and incubated with
primary antibodies in TBS-T+ 3% (w/v) BSA (Sigma).
After washing, blots were incubated with HRP-coupled
secondary antibodies and visualised using Clarity Western
or Clarity Max ECL Substrate (Bio-Rad) on a ChemiDoc
MP imager (Bio-Rad). Primary and secondary antibodies
are listed in Table S1.
Quantitative real-time PCR
Total RNA was extracted from mouse liver using the
RNeasy Mini Kit (QIAGEN). Liver tissue was lysed in
buffer RLT on a TissueLyser II (QIAGEN). Reverse
transcription and real-time PCR were performed as pre-
viously described [32]. See Table S2 for primer
sequences.
Nuclei isolation and DNA content analysis
Isolation of nuclei from livers of 8-week-old OtulinΔhep and
control mice and analysis of their DNA content was per-
formed as previously described [41].
Statistics
Data are presented as individual data points or as means ±
SD or SEM as indicated in figure legends. Red bars
represent means. Sample number (n) represents the number
of independent biological samples in each experiment.
Sample sizes were estimated from pilot experiments. Data
were analysed using the unpaired, two-sided Student’s t test
of the null hypothesis as indicated. Differences in means
were considered statistically significant at P < 0.05. Sig-
nificance levels are: *P < 0.05; **P < 0.01; ***P < 0.001;
****P < 0.0001; n.s., non-significant. Analyses were per-
formed using GraphPad Prism version 7.0b.
Results
Otulin deletion in non-haematopoietic cells causes
acute hepatitis and liver failure
Conditional Otulin knockout (KO) mice have revealed cell
type-specific phenotypes of OTULIN deficiency in immune
cells [31]. However, the role of OTULIN in most non-
haematopoietic cell types is unknown. To investigate the
function of OTULIN in non-haematopoietic cells, we
replaced the bone marrow of Rosa26-Cre-ERT2-Otulinflox
mice [31] with wild type bone marrow to generate chimeric
mice that become OTULIN-deficient exclusively in non-
haematopoietic cells after tamoxifen administration (Otulin-
KOChim mice) (Fig. 1a). Otulin deletion by tamoxifen
administration resulted in weight loss in Otulin-KOChim mice
(Fig. 1b), which was accompanied by highly icteric serum
(Fig. 1c) with a ~12-fold increase in the level of the haem
metabolite bilirubin (Fig. 1d), indicating potential liver failure
in Otulin-KOChim mice. The liver enzymes ALT and AST
were also markedly increased in the Otulin-KOChim serum
(Fig. 1d), indicating damage to the liver parenchyma, and the
number of circulating white blood cells, particularly neu-
trophils, were elevated in the blood (Fig. 1e). Histological
analysis confirmed severe acute hepatitis in the Otulin-KOChim
mice with immune cell infiltration and multiple dead or dying
hepatocytes with nuclear condensation and fragmentation in
the liver (Fig. 1f). In contrast, we observed no obvious
pathology in other tissues when compared with ControlChim
mice (Fig. S1A).
Immunoblot analysis confirmed efficient deletion of
OTULIN in the Otulin-KOChim livers (Figs. 1g and S1B),
and tandem Ub-binding entity (TUBE)-mediated enrich-
ment of Ub conjugates showed increased M1-polyUb levels
in Otulin-KOChim livers compared with controls. Strikingly,
OTULIN deficiency led to marked cleavage and activation
of caspase-3 (Fig. 1g), suggesting that the liver pathology in
Otulin-KOChim mice could involve apoptosis. Only ~2% of
CD45+ immune cells present in peripheral tissues in
the chimeric mice were of parental origin (Fig. S1C, D),
indicating minimal contribution from OTULIN-deficient
immune cells to the observed phenotype.
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Steatotic liver disease in an ORAS patient
Intrigued by the severe liver phenotype in Otulin-KOChim
mice, we hypothesised that liver disease might be an
unrecognised problem in ORAS patients (Fig. 1h). We
retrieved and analysed previously unreported liver biopsies
and records of liver function tests from an ORAS patient
(IV:3) [31]. Liver biopsies from patient IV:3 taken at the
age of 10 and 13 months revealed increasing micro- and
macrosteatosis, hepatocyte degeneration, and the presence
of apoptotic cells, indicating progressive steatotic liver
disease (Fig. 1i). Liver function tests from patient IV:3
performed between the age of 6 weeks and her death at
16 months showed ALT, γGT, and ALP levels clearly
exceeding the normal range (Fig. 1j), supporting the indi-
cation of liver disease in the biopsies. The histopathological
changes in the liver and the elevated liver disease markers in
plasma persisted long after the intravenous total parenteral
nutrition (TPN) was discontinued at the age of ~5 months,
showing that the derangements are not side effects of TPN
feeding (Fig. 1j).
Collectively, our findings show that OTULIN is required
for maintenance of liver homoeostasis in mice and suggest
that ORAS patients may develop liver disease in addition to
the inflammatory manifestations (Fig. 1h) [31, 36]. We
therefore recommend that liver function is monitored clo-
sely in known and future cases of ORAS.
Hepatocyte-specific loss of OTULIN causes
spontaneous steatohepatitis, fibrosis, and
tumourigenesis
To investigate the role of OTULIN and M1-polyUb sig-
nalling in the liver in more detail, we generated mice with
hepatocyte-specific deletion of OTULIN (OtulinΔhep mice)
(Fig. S2A). OtulinΔhep mice were born at the expected
Mendelian frequency but developed obvious liver pathol-
ogy (Fig. 2a). OTULIN protein levels were efficiently
reduced in whole-liver lysates from these mice (Figs. 2b and
S2B). Similar to the Otulin-KOChim mice, OTULIN loss
caused a concomitant increase in M1-polyUb in OtulinΔhep
livers (Figs. 2c and S2C), confirming deregulated M1-
polyUb signalling. Residual OTULIN expression in Otu-
linΔhep livers can be attributed to incomplete penetrance of
Alb-Cre-mediated gene deletion in hepatocytes (Figs. 2b
and S2D) as well as to non-parenchymal liver cells that are
not targeted by Alb-Cre. Expression of the LUBAC com-
ponents HOIP, HOIL-1, and SHARPIN was reduced,
similar to the effect of OTULIN deficiency observed in
lymphocytes and fibroblasts [31, 32], while CYLD levels
remained unchanged (Fig. 2b).
Dissection of livers from young adult OtulinΔhep mice
aged 8–10 weeks revealed severe liver disease with the
presence of multiple macroscopic lesions and nodules
(Fig. 2a). Microscopic examination showed markedly
abnormal liver histology in the OtulinΔhep mice, including
focal steatosis, Mallory–Denk bodies, Kupffer cell hyper-
plasia, and inflammatory foci (Figs. 2d and S2E, F). These
alterations are hallmarks of chronic liver disease and non-
alcoholic steatohepatitis (NASH) [42]. Consistent with
NASH-like disease, PSR staining showed extensive col-
lagen deposition in the OtulinΔhep livers (Fig. 2e, f) with
bridging septa and pericellular fibrosis (Fig. S2G), resem-
bling the fibrotic lesions in human NASH and cirrhosis
[42]. NASH is a risk factor for HCC development [1].
Further examination of the OtulinΔhep livers confirmed that
many of the lesions observed macroscopically (Fig. 2a)
were in fact dysplastic nodules (Figs. 2d and S2F). Across
the parenchyma, we observed prominent variation in size of
nuclei (anisokaryosis), large cell change, and clone-like
growth (Figs. 2d and S2E, F), which are well-established
pre-malignant changes [43]. This liver pathology was fully
penetrant in all OtulinΔhep mice, and we therefore conclude
that OTULIN is intrinsically important in hepatocytes for
preventing severe liver disease.
Despite the absence of hepatomegaly (Fig. S2H), Otu-
linΔhep mice exhibited additional indications of disease,
including increased neutrophil and decreased platelet counts
(Fig. 2g), and an increased proportion of hepatocytes with
polyploid nuclei (Fig. S2I–L), similar to findings in cirrhotic
and NASH livers [42, 44, 45]. Intriguingly, the glycogen
Fig. 1 Liver disease in mice and humans deficient in OTULIN.
a Schematic representation of wild type B6.SJL bone marrow trans-
plantation into γ-irradiated Rosa26-Cre-ERT2-Otulin (R26-Cre-ERT2-
Otulin) mice. b Relative body weight following i.p. administration of
tamoxifen (arrows) to ControlChim (n= 4) and Otulin-KOChim (n= 5)
mice. Each line represents one mouse. Data were pooled from two
independent experiments. c Serum from terminal bleeds of ControlChim
and Otulin-KOChim mice at the end of the experiment shown in (b).
d, e Analysis of bilirubin, ALT, AST, and albumin levels in serum (d)
and blood cell counts (e) from terminal bleeds of ControlChim (n= 4)
and Otulin-KOChim (n= 5) mice at the end of the experiment shown in
(b). Data were pooled from two independent experiments. Data are
presented as individual data points, each representing one mouse. Red
bars indicate means. Data were analysed using an unpaired, two-sided
Student’s t test. n.s., non-significant. f Micrographs of H&E stained
liver sections from ControlChim and Otulin-KOChim mice at the end of
the experiments shown in (b). Arrowheads indicate cells with nuclear
condensation and fragmentation. Micrographs are representative of
two mice in each group. g Immunoblot analysis of whole-liver lysates
and endogenous Ub conjugates purified by TUBE pulldown from
livers of two ControlChim and two Otulin-KOChim mice at the end of the
experiment shown in (b). h Schematic representation of the clinical
manifestations of ORAS. i Micrographs of H&E stained liver sections
from an ORAS patient at the age of 10 and 13 months. Arrowheads
indicate apoptotic cells. j Analysis of ALT, γGT, and ALP levels in
plasma from the ORAS patient shown in (i). Grey shading indicates
period of TPN feeding. Dotted lines indicate upper normal limits of the
test. Each data point represents individual measurements, and red data
points are above the upper normal limits. See also Fig. S1.
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content in OtulinΔhep livers was severely reduced. PAS
staining, which labels polysaccharides, was homogenous
and strong in control livers, whereas OTULIN-deficient
livers showed weak staining with only diffuse PAS-positive
inclusions (Fig. 2h). Reduced glycogen content was asso-
ciated with decreased serum concentrations of glucose, tri-
glycerides, and cholesterol (Fig. 2i), despite normal insulin
levels (Fig. 2j). These results indicate a disruption in
metabolic function that could contribute to development of
liver disease in OtulinΔhep mice.
OTULIN deficiency in the liver leads to cell death
and inflammation
Hepatocyte damage and cell death promotes inflammation
and NASH development [4]. We investigated if the
pathology in OtulinΔhep livers was associated with cell death
and inflammation. Compared with controls, we observed
increased numbers of TUNEL-positive dead cells and Ki67-
positive proliferating cells in OTULIN-deficient livers
(Fig. 3a–c). Serum from OtulinΔhep mice also contained
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higher levels of ALT, AST, and bilirubin (Fig. 3d, e),
consistent with hepatocyte cell death and a moderate
reduction in liver function, while albumin levels remained
normal (Fig. 3e). Similar to the chimeric mice, immunoblot
analysis of liver lysates showed increased caspase-3 acti-
vation in OtulinΔhep mice compared with controls (Figs. 3f
and S3A).
Cell death and proliferation in the OtulinΔhep livers was
associated with elevated mRNA levels of the pro-
inflammatory cytokines TNF, IL-6, and IL-1β as well as
the NF-κB and apoptosis regulator A20 (Tnfaip3) and the
Kupffer cell marker CD68 (Fig. 3g), clearly indicating liver
inflammation. Inflammation is a key inducer of collagen-
producing myofibroblasts [2]. Consistent with collagen
deposition in OTULIN-deficient livers (Fig. 2d), the tran-
script level of smooth muscle actin (Acta2), a myofibroblast
marker, was also significantly increased (Fig. 3g), implying
myofibroblast expansion. Interestingly, inflammation in the
OTULIN-deficient livers was not associated with any
appreciable increase in basal NF-κB or MAP kinase acti-
vation. Immunoblot analysis showed that phosphorylation
of NF-κB p65/RelA and the MAP kinases ERK1/2 and p38
was comparable in OtulinΔhep and control livers, as was the
expression of the NF-κB inhibitor inhibitor-of-κBα
(Figs. 3h and S3B). The absence of increased NF-κB sig-
nalling is similar to previous reports from OTULIN-
deficient fibroblasts, which are sensitised to induction of
apoptosis rather than NF-κB hyper-signalling [32, 33],
suggesting that an NF-κB-independent mechanism, e.g.
apoptosis or altered metabolism, is responsible for the
OtulinΔhep pathology.
Development of HCC in OTULIN-deficient livers
Chronic inflammation and NASH predispose to develop-
ment of HCC [1, 2]. To examine whether the NASH-like
pathology in young OtulinΔhep mice might lead to cancer,
we analysed the OTULIN-deficient livers for signs of
neoplasia and HCC. OtulinΔhep livers contained multiple
pre-malignant tumours (Figs. 2d and 4a) and ~60 macro-
scopic lesions per liver (Fig. 4b) at 8–10 weeks. The pre-
malignant lesions in OtulinΔhep livers were accompanied by
a dramatic increase in serum levels of the liver cancer
marker AFP (Fig. 4c) as well as the expression of many
cancer-associated genes, including the HCC markers
Ccnd1, Ctgf, Gpc3, and Igf2; the onco-foetal markers Afp
and H19; and the cancer stem cell markers Klf4, Aldh1, and
Cd133/Prom1 (Fig. 4d). This suggested that young Otu-
linΔhep mice were likely to develop HCC.
Indeed, dissection of livers from OtulinΔhep mice aged
50–54 weeks revealed the presence of multiple large
tumours (Fig. 4e). The tumour incidence (presence of a
tumour ≥2 mm in diameter) was 100% in OtulinΔhep mice
while no lesions were observed in controls (Fig. 4f). While
the tumour size, number, and severity varied in OtulinΔhep
mice, nearly half of them presented with major pathology
(tumour > 10 mm in diameter; 14/30) (Fig. 4g). Many mice
with major pathology had highly vascularised tumours
(Fig. 4e, arrowheads, and S4A). Approximately one third of
the OtulinΔhep mice developed moderate pathology (tumour
5–10 mm in diameter; 11/30), and only a few mice devel-
oped mild pathology (tumour 2–5 mm in diameter; 5/30)
(Fig. 4e–h). Microscopic examination uncovered the pre-
sence of malignant tumours corresponding to well and
moderately differentiated HCC (Fig. 4i) [46]. The analysed
tumours were characterised by expansive growth and the
absence of portal tracts (Fig. 4i), broad trabecular growth
(>4 cells wide) (Fig. 4i, ii), increased eosinophilia (ii and iii)
or cell clearance (iv), increased number of mitotic figures
(iii, arrowheads), as well as high pleomorphism and atypical
nuclei (iv), all indicative of malignant HCC [46]. Occa-
sionally, tumours also showed focal necrosis and cystic
degeneration (Fig. S4B), indicating fast-growing and
aggressive tumours. Pre-malignant dysplastic nodules with
severe anisokaryosis and atypic nuclei were also present
[47]. Analysis of OtulinΔhep mice aged 32 weeks revealed
moderate pathology (Fig. S4C) and the presence of well
differentiated tumours (Fig. S4D), occasionally with poor
demarcation and the absence of portal tracts, indicating that
Fig. 2 Steatohepatitis, fibrosis, and spontaneous tumour formation
in OtulinΔhep mice. a Representative macroscopic appearance of
OtulinΔhep and control livers at the age of 8–10 weeks. Scale bars
indicate 1 cm. b Immunoblot analysis of OTULIN, LUBAC, and
CYLD expression in whole-liver lysates from three OtulinΔhep and
three control mice aged 8–10 weeks. c Immunoblot analysis of whole-
liver lysates and endogenous Ub conjugates purified by M1-SUB
pulldown from livers of three control and three OtulinΔhep mice.
d Micrographs of H&E stained liver sections from OtulinΔhep and
control mice aged 8–10 weeks. Top panels show pale-staining hepa-
tocyte clones with fat accumulation in OtulinΔhep mice. Bottom panels
show inflammation, fat accumulation, and variations in nuclear size in
OtulinΔhep livers. Micrographs are representative of eight mice of each
genotype. e Micrographs of PSR stained liver sections from OtulinΔhep
and control mice aged 8–10 weeks show fine bridging porto-portal and
porto-central fibrous septa with areas of pericelluar fibrosis in Otu-
linΔhep mice. Micrographs are representative of six mice of each gen-
otype. f Quantification of PSR-positive (fibrotic) area in liver sections
from OtulinΔhep (n= 6) and control (n= 6) mice aged 8–10 weeks.
g Neutrophil and platelet counts from terminal bleeds of OtulinΔhep
(n= 6) and control (n= 6) mice aged 8–10 weeks. h Micrographs of
PAS stained liver sections from OtulinΔhep and control mice aged
8–10 weeks show pale-staining hepatocytes in OtulinΔhep mice due to
loss of glycogen. Micrographs are representative of five controls and
six OtulinΔhep mice. i, Analysis of glucose, triglyceride, and choles-
terol levels in serum from terminal bleeds of OtulinΔhep (n= 15) and
control (n= 8) mice aged 8–10 weeks. j Analysis of insulin levels in
serum from terminal bleeds of OtulinΔhep (n= 8) and control (n= 6)
mice aged 8–10 weeks. f, g, i, j Data are presented as individual data
points, each representing one mouse. Red bars indicate means. Data
were analysed using an unpaired, two-sided Student’s t test. n.s., non-
significant. See also Fig. S2.
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these are early neoplastic tumours. This indicates that
malignancy arises between 32 and 50 weeks of age in
OtulinΔhep mice.
Steatohepatitis in OtulinΔhep mice is independent of
TNFR1 signalling
TNF is the primary driver of inflammation in both ORAS
patients and ORAS mouse models [31, 32, 36]. Dysregu-
lated TNFR1 signalling also contributes to development of
liver disease and cancer [4], and liver-specific deletion of
the M1/K63-specific DUB CYLD causes TNFR1-mediated
hepatitis and HCC [48]. We therefore investigated if
TNFR1 signalling contributed to the liver pathology in
OtulinΔhep mice. Surprisingly, co-deletion of Tnfr1 (p55-
TNFR1) in OtulinΔhep mice did not prevent the development
of liver disease (Figs. 5a and S5A). OtulinΔhep and Otu-
linΔhep;Tnfr1−/− mice aged 8–12 weeks developed indis-
tinguishable pathology (Fig. 5a, b). Microscopic
examination revealed virtually identical abnormal histology
with dysplastic nodules, large cell change, anisokaryosis,
and cytoplasmic inclusions in both OtulinΔhep and
Fig. 3 Liver disease in OtulinΔhep mice is associated with hepato-
cyte cell death, proliferation, and inflammation. a TUNEL (top
panels) and anti-Ki67 (bottom panels) stainings of liver sections from
OtulinΔhep and control mice aged 8–10 weeks. Data are representative
of six mice of each genotype for TUNEL staining and three controls
and eight OtulinΔhep mice for Ki67. b, c Quantification of TUNEL- (b)
and Ki67-positive (c) cells in liver from OtulinΔhep and control at the
age of 8–10 weeks as shown in (a). TUNEL (b), OtulinΔhep (n= 6) and
control (n= 6), and anti-Ki67 (c), OtulinΔhep (n= 8) and control (n=
3). d, e Analysis of ALT and AST (d) or bilirubin and albumin (e)
levels in serum from terminal bleeds of OtulinΔhep (n= 6) and control
(n= 6) mice aged 8–10 weeks. f Immunoblot analysis of caspase-3
cleavage in whole-liver lysate from livers of three control and three
OtulinΔhep mice aged 8–10 weeks. g Relative mRNA expression of Tnf,
Il6, Il1b, Tnfaip3, Cd68, and Acta2 in livers from OtulinΔhep (n= 8)
and control (n= 8) aged 8–10 weeks measured by quantitative RT-
PCR. h Immunoblot analysis of NF-κB p65/RelA and MAP kinase
activation in whole-liver lysate from livers of three control and three
OtulinΔhep mice aged 8–10 weeks. b–e, g Data are presented as indi-
vidual data points, each representing one mouse. Red bars indicate
means. Data were analysed using an unpaired, two-sided Student’s t
test. n.s., non-significant. See also Fig. S3.
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OtulinΔhep;Tnfr1−/− mice (Fig. 5c, top panels, and S5B).
The extent and pattern of fibrosis was also unaffected by the
deletion of TNFR1 (Fig. 5c, bottom panels, and 5d). Serum
levels of ALT and AST, which reflect the degree of cell
death in the liver [4], were not significantly reduced in the
OtulinΔhep;Tnfr1−/− mice either (Fig. 5e), and neither were
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the cleavage and activation of caspase-3 nor the activation
of NF-κB p65/RelA (Fig. S5C). The macroscopic pathology
of OtulinΔhep and OtulinΔhep;Tnfr1−/− mice remained indis-
tinguishable until at least the age of 20–25 weeks
(Fig. S5D). We therefore conclude that the cellular aberra-
tions leading to liver disease in OtulinΔhep mice are inde-
pendent of TNFR1 signalling and thus distinct from the
pathology in CYLD-deficient livers [48].
Prominent neonatal steatosis and aberrant mTOR
activation in OtulinΔhep mice
As the phenotype in young adult OtulinΔhep mice was
independent of TNFR1 signalling, we examined livers from
younger OtulinΔhep mice to define the onset of the pheno-
type. Analysis of neonatal OtulinΔhep and control livers at
postnatal day (P) 3 and P9 showed that OTULIN ablation
was efficient at this age and that HOIP expression was
reduced (Fig. S6A–D), similar to our observations at
8–10 weeks. Strikingly, neonatal OtulinΔhep mice displayed
noticeable steatosis at P3 and P9 (Figs. 6a, b and S6E), akin
to the liver disease in the infant ORAS patient (Fig. 1i). The
neonatal OtulinΔhep livers were pale and oily, particularly at
P9 (Fig. 6a). The cholesterol level in serum was also
increased at P9 (Fig. 6c), while triglyceride and glucose
levels were comparable in OtulinΔhep and control mice
(Fig. S6F). Histopathological examination indicated
progressive lipid accumulation, mainly microsteatosis,
between P3 and P9 in OtulinΔhep mice (Figs. 6b, top and
centre panels, and S6E), and lipid-specific Oil Red O
staining confirmed prominent steatosis in the P9 livers
(Fig. 6b, bottom panels, and 6d).
Immunohistochemical analysis showed an increase in
TUNEL-positive cells in the OtulinΔhep livers at P9 (Fig. 6e,
top panels, and 6f), comparable with the increase observed
at 8–10 weeks. Both at P3 and P9, caspase-3 cleavage was
also increased (Figs. S6A, C). The number of Ki67-positive
proliferating cells was also elevated in the P9 OtulinΔhep
livers, although only marginally (Fig. 6e, bottom panels,
and 6g), likely due to the fact that the liver at this age is a
highly proliferative organ already. In contrast, we did not
detect any signs of collagen deposition at either P3 or P9 in
these mice (Fig. S6G, H).
The kinase mTOR is a master regulator of cellular
metabolism and growth [3], and increased mTOR activity
promotes liver cancer development in mice [49, 50]. In
models of mTOR-driven carcinogenesis, metabolic altera-
tions accompany hepatocyte damage and proliferation
[49, 50], akin to our observations in OtulinΔhep mice. We
therefore investigated if mTOR signalling was altered in
OtulinΔhep livers. Intriguingly, we observed aberrant mTOR
activity in P9 OtulinΔhep livers compared with controls
(Fig. 6h and S6D). When compared with the overall lower
expression of total mTOR protein in P9 OtulinΔhep liver
lysates, the relative phosphorylation of the activating
Ser2448 in mTOR was increased compared with controls
(Fig. 6h). This correlated with increased phosphorylation of
the mTOR complex 1 (mTORC1)-dependent substrates S6
ribosomal protein (S6rp) and carbamoyl-phosphate synthe-
tase, aspartate transcarbamylase, and dihydroorotase (CAD)
(Fig. 6h). S6rp phosphorylation was also increased in P3
livers (Fig. S6H). Phosphorylation of mTOR and its sub-
strates correlated with reduced levels of the TSC complex
(consisting of TSC1 and TSC2), a negative regulator of
mTOR, and increased expression of the mTOR activator
Rheb in P9 OtulinΔhep livers (Figs. 6h and S6I). At
8–10 weeks, OTULIN-deficient livers showed more nor-
mal, but still slightly increased, mTORC1 activation
(Figs. 6i and S6J). The expression of the TSC complex was
comparable with controls, but Rheb expression was still
increased (Fig. 6i). We observed no apparent increase in
phosphorylation of the mTORC2 substrate Akt (Ser473)
(Fig. 6h, i). These findings indicate that OTULIN deficiency
leads to aberrant mTORC1 activation.
mTOR inhibition reduces liver disease in OtulinΔhep
mice
In humans, mTOR activity is upregulated in 40–50% of
HCC cases and is associated with poor prognosis [51]. In
Fig. 4 Hepatocellular carcinoma in OtulinΔhep mice. a Micrographs
of H&E stained liver sections from OtulinΔhep and control mice aged
8–10 weeks. The dotted line indicates two subcapsular tumours.
Micrographs are representative of eight mice of each genotype. Tu,
tumour. b Quantification of the number of macroscopically discernible
lesions (tumours, nodules, and discolourations) in OtulinΔhep and
control mice aged 8–10 weeks. Data are representative of four mice of
each genotype. c Analysis of AFP levels in serum from terminal bleeds
of OtulinΔhep (n= 6) and control (n= 6) mice aged 8–10 weeks.
d Relative mRNA expression of the indicated cancer markers in livers
from OtulinΔhep (n= 8) and control (n= 8) aged 8–10 weeks measured
by quantitative RT-PCR. e Representative macroscopic appearance of
OtulinΔhep and control livers at the age of 50–54 weeks, grouped by
severity. Arrowheads indicate highly vascularised tumours. Scale bars
indicate 1 cm. f, g Quantification of the number of mice with the
presence of a tumour ≥2 mm in diameter (f) or the number of mice in
each severity group as indicated (g) in OtulinΔhep and control mice at
the age of 50–54 weeks. h Maximal tumour size in OtulinΔhep mice,
grouped by degree of pathology. Each data point represents the
maximal tumour size in one mouse. Red bars indicate means ± SD.
i Micrographs of H&E stained liver sections from OtulinΔhep and
control mice aged 50–54 weeks. (i) shows a control liver, (ii) shows
HCC with abnormal macrotrabecular pattern, (iii) shows raised
nuclear-cytoplasmic ratio, irregular nuclear outlines, and several
mitotic figures (arrowheads), and (iv) shows a tumour with a steato-
hepatic appearance, with also enlarged and irregular nuclei. Micro-
graphs are representative of four controls and 15 OtulinΔhep mice. Tu
tumour. NT non-tumour. b–d Data are presented as individual data
points, each representing one mouse. Red bars indicate means. Data
were analysed using an unpaired, two-sided Student’s t test. n.s., non-
significant. See also Fig. S4.
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mice, increased mTOR activity leads to HCC development,
which can be counter acted by treatment with mTOR
inhibitors [49, 50]. To examine if OTULIN deficiency led to
mTOR-driven liver disease, we tested if inhibition of
mTOR could reduce the pathology in the OtulinΔhep mice.
As aberrant mTOR activation is evident already at P3, we
treated OtulinΔhep mice with rapamycin from birth until the
age of 8 weeks. Rapamycin treatment was not well tolerated
in OtulinΔhep mice. Treated OtulinΔhep mice displayed
reduced weight gain when compared with vehicle-treated
mice and even rapamycin-treated controls (Fig. S7A),
demonstrating a pharmacogenetic interaction between
OTULIN deficiency and mTOR inhibition. The condition of
the rapamycin-treated OtulinΔhep mice meant that for many
mice the experiment had to be stopped at 6 weeks of age
(Fig. S7A).
Remarkably, despite early termination of the experiment,
rapamycin treatment reduced the pathology in OtulinΔhep
Fig. 5 Liver disease in OtulinΔhep mice is independent of
TNFR1 signalling. a Representative macroscopic appearance of livers
from OtulinΔhep mice, OtulinΔhep;Tnfr1−/− mice, and their respective
controls at the age of 8–12 weeks. Scale bar indicates 1 cm.
b Quantification of the number of macroscopically discernible lesions
(tumours, nodules, and discolourations) in OtulinΔhep (n= 7) and
OtulinΔhep;Tnfr1−/− (n= 5) mice aged 8–12 weeks. c Micrographs of
liver sections from OtulinΔhep mice, OtulinΔhep;Tnfr1−/− mice, and their
respective controls at the age of 8–12 weeks stained with H&E or PSR
as indicated. d Quantification of PSR-positive (fibrotic) area in liver
sections OtulinΔhep mice, OtulinΔhep;Tnfr1−/− mice, and their respective
controls at the age of 8–12 weeks. e Analysis of ALT and AST
levels in serum from terminal bleeds of OtulinΔhep mice, OtulinΔhep;
Tnfr1−/− mice, and their respective controls at the age of 8–12 weeks.
b, d, e Data are presented as individual data points, each representing
one mouse. Red bars indicate means. Data were analysed using
unpaired, two-sided Student’s t tests. n.s., non-significant. See also
Fig. S5.
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livers compared with vehicle-treated OtulinΔhep mice of the
same age (Fig. 7a). Rapamycin treatment reduced both the
number and size of macroscopic lesions in the livers, but it
did not completely prevent liver disease (Fig. 7a, b). The
livers from the rapamycin-treated OtulinΔhep mice appeared
smaller than vehicle-treated OtulinΔhep mice or rapamycin-
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treated controls (Fig. 7a), but relative to body weight they
were not different from vehicle-treated OtulinΔhep livers
(Fig. S7B). Microscopically, rapamycin reduced the histo-
logical abnormalities and the number of dysplastic foci and
nodular growths in the OtulinΔhep livers (Figs. 7c and S7C).
Hepatocyte dysplasia and the inflammatory cells in the
parenchyma were decreased in the rapamycin-treated Otu-
linΔhep livers, although some of the cellular changes,
including atypical nuclei and hepatocyte hypertrophy, per-
sisted (Fig. 7c, inserts). In addition, rapamycin treatment
significantly reduced fibrosis in OtulinΔhep mice (Fig. 7c, d).
Importantly, ALT and AST levels in serum were not sig-
nificantly reduced by mTOR inhibition (Fig. 7e), suggesting
that apoptosis in OtulinΔhep livers is independent of mTOR.
Our findings demonstrate that mTOR activity promotes
fibrosis and liver disease in OtulinΔhep mice, but also that
mTOR inhibition by rapamycin is insufficient to completely
prevent liver pathology in these mice.
Discussion
We provide evidence that OTULIN is a crucial in vivo
regulator of liver homoeostasis in mice and humans, iden-
tify mTOR signalling as a surprising driver of liver disease
in OTULIN-deficient mice, and show that mTOR inhibition
with rapamycin can improve liver pathology caused by
OTULIN deficiency. In humans, OTULIN deficiency cau-
ses a severe autoinflammatory syndrome, ORAS
[31, 32, 36, 37], and genetic ablation of OTULIN in
immune cells in mice replicate many inflammatory hall-
marks of ORAS [31]. Our discovery that OTULIN defi-
ciency also causes severe liver disease in humans and mice
expands the range of pathologies associated with OTULIN
and highlights the critical importance of proper regulation
of M1-polyUb signalling.
OtulinΔhep livers exhibit early-onset progressive liver
disease. Within days of birth, OtulinΔhep mice develop
steatosis. As the Alb-Cre transgene is expressed in the late
foetal stages [52], the neonatal steatosis in OtulinΔhep mice
may result from signalling responses or other priming
events onset before birth. It will be important to delineate
these foetal events and their contribution to the phenotype
in future studies.
By the age of 8 weeks, the neonatal steatosis in Otu-
linΔhep mice has developed into steatohepatitis, fibrosis, and
pre-malignant tumours, and HCC by the age of
7–12 months. This pattern of disease progression—from
steatosis to steatohepatitis, fibrosis, and HCC—is remark-
ably similar to the advancement of liver disease in human
NASH patients [1, 42]. NASH-like steatohepatitis and HCC
also develops in mice with liver-specific deletion of the M1-
polyUb DUB CYLD [48]. In these mice, the apoptosis and
compensatory regeneration that drives the pathogenesis is
completely dependent on TNFR1. Surprisingly, unlike
CYLD-deficient livers, TNFR1 signalling is dispensable for
steatohepatitis and pre-malignant tumour development in
OtulinΔhep livers, clearly indicating that the liver diseases
caused by deficiency in the two main M1-polyUb-
regulating DUBs, OTULIN, and CYLD, have distinct
pathogeneses. In contrast to OTULIN, which is strictly M1
linkage-specific [25, 26], CYLD cleaves both M1 and K63
linkages [27]. The apparent difference in steatohepatitis
pathogenesis caused by deficiency in these two DUBs could
therefore arise from combined dysregulation of M1- and
K63-polyUb signalling in the CYLD-deficient livers but
exclusively M1-polyUb dysregulation in OTULIN-deficient
livers. In addition, dysregulation of LUBAC complexes
could contribute to the observed differences [8]. OTULIN
and CYLD form mutually exclusive complexes with
LUBAC [53]. In the absence of OTULIN, only CYLD-
SPATA2-LUBAC complexes can form [54–57], and con-
versely, without CYLD, only OTULIN-LUBAC complexes
can assemble [28–30]. Dysregulation of the LUBAC-
independent OTULIN-SNX27 complex could also be
involved [58].
Our examination of neonatal OtulinΔhep livers revealed an
unexpected phenotype of steatosis and aberrant mTOR sig-
nalling. Remarkably, mTOR inhibition by rapamycin
administration reduces liver pathology in OtulinΔhep mice. To
our knowledge, this is the first report of a link between M1-
polyUb and mTOR. Both degradative and non-degradative
ubiquitination can regulate mTOR pathways [59], but
Fig. 6 Steatosis and aberrant mTOR activation in neonatal Otu-
linΔhep mice. a Representative macroscopic appearance OtulinΔhep and
control livers at the age of 9 days. Scale bar indicates 1 cm.
b Micrographs of liver sections from OtulinΔhep and control mice at the
age of 9 days stained with H&E and Oil Red O as indicated. H&E
staining shows pale hepatocytes with varying sized vacuoles in Otu-
linΔhep mice, which is confirmed as fat by Oil Red O staining.
Micrographs are representative of seven controls and six OtulinΔhep
mice for H&E, and three controls and five OtulinΔhep mice for Oil Red
O. c Analysis of cholesterol levels in serum from terminal bleeds of
OtulinΔhep (n= 9) and control (n= 6) mice at the age of 9 days.
d Quantification of Oil Red O-positive area (left) and number of lipid
droplets (right) in liver sections OtulinΔhep (n= 5) and control (n= 3)
at the age of 9 days as shown in (b). e TUNEL (top panels) and anti-
Ki67 (bottom panels) stainings of liver sections from OtulinΔhep and
control mice aged 9 days. Data are representative of four control and
three OtulinΔhep mice for TUNEL, and three controls and five Otu-
linΔhep mice for Ki67. f, g Quantification of TUNEL- (f) and Ki67-
positive (g) cells in liver from OtulinΔhep and control at the age of
9 days as shown in (e). TUNEL (f), OtulinΔhep (n= 3) and control (n=
4), and anti-Ki67 (g), OtulinΔhep (n= 5) and control (n= 3). h, i Im-
munoblot analysis of mTOR pathway components and activation in
whole-liver lysate from three OtulinΔhep mice and three controls aged
9 days (h) and 8–10 weeks (i). c, d, f, g Data are presented as indi-
vidual data points, each representing one mouse. Red bars indicate
means. Data were analysed using an unpaired, two-sided Student’s
t test. n.s., non-significant. See also Fig. S6.
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no direct link to M1-polyUb has been reported. OTULIN
deficiency appears to cause changes in the expression of
mTOR regulators, such as the TSC complex and Rheb, in the
liver, likely leading to aberrant mTOR activation. However,
the molecular nature of this dysregulation, and whether it is a
direct effect or part of a secondary regenerative response, is
unclear. Intriguingly, mTOR signalling can regulate inflam-
matory processes and apoptosis [60], and a link between
OTULIN, M1-polyUb, and mTOR could potentially connect
the metabolic alterations and inflammation observed in
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OtulinΔhep mice. However, more mechanistic studies are
needed to elucidate any molecular link between M1-polyUb
and mTOR.
In summary, we demonstrate that OTULIN prevents cell
death, inflammation, and metabolic derangements in the
liver and can act as a tumour suppressor in mice (Fig. 7f).
This highlights how delicately balanced M1-polyUb sig-
nalling must be to prevent disease. Moreover, the pathology
in OTULIN-deficient livers is partially dependent on mTOR
activity and can be ameliorated by rapamycin treatment.
This suggests a role for OTULIN in mTOR regulation and
implicates M1-polyUb in cellular signalling processes
beyond control of NF-κB and TNF-mediated cell death.
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